Shareholders' Equity (Details) - USD ($)					1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 17, 2017	Aug. 17, 2017	Jul. 10, 2017	Jun. 06, 2017	Feb. 28, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Apr. 06, 2017	Dec. 31, 2016
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)						2,000,000	2,000,000			2,000,000
Preferred shares, shares issued (in shares)						0	0			0
Preferred shares, shares outstanding (in shares)						0	0			0
Common Shares [Abstract]
Common stock, shares authorized (in shares)						150,000,000	150,000,000			150,000,000
Common stock, par value (in dollars per share)						$ 0	$ 0			$ 0
Common stock, issued (in shares)						115,804,040	115,804,040			103,396,245
Common stock, outstanding (in shares)						115,804,040	115,804,040			102,776,539
Treasury stock (in shares)						0	0			619,706
Noncash expense							$ 2,903,000	$ 6,303,000
Proceeds from sale of common shares of subsidiary							$ 9,968,000	$ 0
Transfer of ownership at carrying value				$ 3,100,000
Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)	11,057,693				7,453,704
Purchase price per share (in dollars per share)	$ 2.60				$ 2.70
Proceeds from sale of stock	$ 26,700,000				$ 18,500,000
Cell Cure Neurosciences, Ltd. [Member]
Common Shares [Abstract]
Ownership percentage			99.80%			62.50%	62.50%
Cell Cure Neurosciences, Ltd. [Member] | General and Administrative Expenses [Member]
Common Shares [Abstract]
Noncash expense						$ 531,000	$ 531,000
Cell Cure Neurosciences, Ltd. [Member] | Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)			2,147,880
Common shares issued value			$ 6,600,000
LifeMap Sciences, Inc. [Member]
Common Shares [Abstract]
Ownership percentage				82.00%						78.00%
Percentage of outstanding shares contributed to acquire subsidiary							82.00%
LifeMap Solutions, Inc [Member]
Common Shares [Abstract]
Ownership percentage				100.00%
Hadasit Bio-Holdings, Ltd [Member]
Common Shares [Abstract]
Ownership percentage, noncontrolling owners			21.20%
Warrants issued to purchase ordinary shares (in shares)			24,566
Warrants exercise price (in dollars per share)			$ 40.5359
Warrants exercisable term							5 years
Hadasit Bio-Holdings, Ltd [Member] | Other Long-Term Liabilities [Member]
Common Shares [Abstract]
Value of warrants						531,000	$ 531,000
Teva Pharmaceutical Industries, Ltd [Member]
Common Shares [Abstract]
Ownership percentage, noncontrolling owners			16.10%
Warrants issued to purchase ordinary shares (in shares)			0
AgeX [Member]
Common Shares [Abstract]
Number of shares sold (in shares)		4,950,000
Ownership percentage		85.00%
Number of shares acquired from subsidiary in terms exchange (in shares)		28,800,000
Proceeds from sale of common shares of subsidiary		$ 10,000,000
Cash contributed to acquire subsidiary							100,000
Carrying value of equity transfer						$ 8,200,000	$ 8,200,000
ReCyte Therapeutics, Inc. [Member]
Common Shares [Abstract]
Percentage of outstanding shares contributed to acquire subsidiary							95.00%
Ascendance Biotechnology, Inc. [Member]
Common Shares [Abstract]
Percentage of outstanding shares contributed to acquire subsidiary							44.00%
Cantor Fitzgerald & Co [Member]
Common Shares [Abstract]
Percentage of commission payable							3.00%
Cantor Fitzgerald & Co [Member] | Maximum [Member]
Common Shares [Abstract]
Aggregate offering price									$ 25,000,000